New antibody injection could ease bulging eyes in thyroid disease
NCT ID NCT06989918
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests MHB018A, an antibody injection, against placebo in 108 people with active moderate-to-severe thyroid eye disease. Participants receive six injections over 24 weeks. The main goal is to see if the drug reduces eye bulging by at least 2 mm without worsening the other eye.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MHB018A (a humanized antibody targeting IGF-1 receptor)
What this could lead to
If successful, this could provide a new treatment option to reduce eye bulging and inflammation in people with active thyroid eye disease.
What could go wrong
This is a relatively small Phase 3 trial (108 participants), and the drug may not work better than placebo. Possible side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 201419, China
Contact Phone: •••-•••-•••• Email: •••••@•••••